Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis

Clinical Microbiology and Infection

Volumn 23, Issue 4, 2017, Pages 234-241

  Vardakas, K Z ^a,b   Trigkidis, K K ^a,c   Falagas, M E ^a,b,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Azithromycin; Carbapenem; Cephalosporin; Ciprofloxacin; Clarithromycin; Levofloxacin; Moxifloxacin; Penicillin

Indexed keywords

BETA LACTAM ANTIBIOTIC; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; BETA LACTAM; QUINOLONE DERIVATIVE;

AMERICAN; ANTIBIOTIC THERAPY; BACTEREMIA; COCHRANE LIBRARY; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; EUROPEAN; HOSPITAL PATIENT; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; SEPTIC SHOCK; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADULT; COMMUNITY-ACQUIRED INFECTIONS; HOSPITALIZATION; MICROBIOLOGY; ODDS RATIO; PNEUMONIA, BACTERIAL; SHOCK, SEPTIC;

ADULT; BACTEREMIA; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HOSPITALIZATION; HUMANS; MACROLIDES; ODDS RATIO; PNEUMONIA, BACTERIAL; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 85009174984     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.12.002     Document Type: Review

References (52)

1. [1] Tong, N., Update on 2004 Background Paper. BP 6.22 Pneumonia, 2013 Accessed 15 June 2016. Available at: http://www.who.int/medicines/areas/priority_medicines/BP6_22Pneumo.pdf.
2. [2] Broulette, J., Yu, H., Pyenson, B., Iwasaki, K., Sato, R., The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits 6 (2013), 494–503.
3. [3] File, T.M. Jr., Marrie, T.J., Burden of community-acquired pneumonia in North American adults. Postgrad Med 122 (2010), 130–141.
4. [4] Lee, J.S., Giesler, D.L., Gellad, W.F., Fine, M.J., Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review. JAMA 315 (2016), 593–602.
5. [5] Hoffken, G., Lorenz, J., Kern, W., Welte, T., Bauer, T., Dalhoff, K., et al. Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and of the Competence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community-acquired Pneumonia. Pneumologie 64 (2010), 149–154.
6. [6] Lim, W.S., Baudouin, S.V., George, R.C., Hill, A.T., Jamieson, C., Le Jeune, I., et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64:Suppl 3 (2009), 1–55.
7. [7] Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:Suppl 2 (2007), S27–S72.
8. [8] Spindler, C., Stralin, K., Eriksson, L., Hjerdt-Goscinski, G., Holmberg, H., Lidman, C., et al. Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults–Swedish Society of Infectious Diseases 2012. Scand J Infect Dis 44 (2012), 885–902.
9. [9] Wiersinga, W.J., Bonten, M.J., Boersma, W.G., Jonkers, R.E., Aleva, R.M., Kullberg, B.J., et al. SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. Neth J Med 70 (2012), 90–101.
10. [10] Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect 17:Suppl 6 (2011), E1–E59.
11. [11] Zuckerman, J.M., Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am, 18, 2004 621–49, xi.
12. [12] Menendez, R., Torres, A., Aspa, J., Capelastegui, A., Prat, C., Rodriguez de Castro, F., Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR). Arch Bronconeumol 46 (2010), 543–558.
13. [13] Garin, N., Genne, D., Carballo, S., Chuard, C., Eich, G., Hugli, O., et al. beta-Lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 174 (2014), 1894–1901.
14. [14] Postma, D.F., van Werkhoven, C.H., van Elden, L.J., Thijsen, S.F., Hoepelman, A.I., Kluytmans, J.A., et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372 (2015), 1312–1323.
15. [15] Vardakas Siempos, K.Z. II, Grammatikos, A., Athanassa, Z., Korbila, I.P., Falagas, M.E., Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 179 (2008), 1269–1277.
16. [16] Lee, J.S., Fine, M.J., The debate on antibiotic therapy for patients hospitalized for pneumonia: where should we go from here?. JAMA Intern Med 174 (2014), 1901–1903.
17. [17] Nie, W., Li, B., Xiu, Q., beta-Lactam/macrolide dual therapy versus beta-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother 69 (2014), 1441–1446.
18. [18] Torres, A., Garau, J., Arvis, P., Carlet, J., Choudhri, S., Kureishi, A., et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study–a randomized clinical trial. Clin Infect Dis 46 (2008), 1499–1509.
19. [19] Infectious Society of America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005), 388–416.
20. [20] Slim, K., Nini, E., Forestier, D., Kwiatkowski, F., Panis, Y., Chipponi, J., Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73 (2003), 712–716.
21. [21] Guyatt, G.H., Oxman, A.D., Kunz, R., Vist, G.E., Falck-Ytter, Y., Schunemann, H.J., What is “quality of evidence” and why is it important to clinicians?. BMJ 336 (2008), 995–998.
22. [22] Effect estimates and generic inverse variance meta-analysis. Available at: http://handbook.cochrane.org/chapter_7/7_7_7_1_effect_estimates_and_generic_inverse_variance.htm.
23. [23] Rottier, W.C., Ammerlaan, H.S., Bonten, M.J., Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 67 (2012), 1311–1320.
24. [24] Adrie, C., Schwebel, C., Garrouste-Orgeas, M., Vignoud, L., Planquette, B., Azoulay, E., et al. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance. Crit Care, 17, 2013, R265.
25. [25] Bratzler, D.W., Ma, A., Nsa, W., Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project. Clin Infect Dis 47:Suppl 3 (2008), S193–S201.
26. [26] Capelastegui, A., Espana, P.P., Quintana, J.M., Gorordo, I., Martinez Urquiri, A., Idoiaga, I., et al. Patients hospitalized with community-acquired pneumonia: a comparative study of outcomes by medical specialty area. Arch Bronconeumol 41 (2005), 300–306.
27. [27] Capelastegui, A., Espana, P.P., Quintana, J.M., Gorordo, I., Sanudo, C., Bilbao, A., Evaluation of clinical practice in patients admitted with community-acquired pneumonia over a 4-year period. Arch Bronconeumol 42 (2006), 283–289.
28. [28] Charles, P.G., Whitby, M., Fuller, A.J., Stirling, R., Wright, A.A., Korman, T.M., et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 46 (2008), 1513–1521.
29. [29] Frei, C.R., Restrepo, M.I., Mortensen, E.M., Burgess, D.S., Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 119 (2006), 865–871.
30. [30] Houck, P.M., MacLehose, R.F., Niederman, M.S., Lowery, J.K., Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 119 (2001), 1420–1426.
31. [31] Karhu, J., Ala-Kokko, T.I., Ohtonen, P., Syrjala, H., Severe community-acquired pneumonia treated with beta-lactam-respiratory quinolone vs. beta-lactam-macrolide combination. Acta Anaesthesiol Scand 57 (2013), 587–593.
32. [32] Mahboub, B., Al Zaabi, A., Al Ali, O.M., Ahmed, R., Niederman, M.S., El-Bishbishi, R., Real life management of community-acquired Pneumonia in adults in the Gulf region and comparison with practice guidelines: a prospective study. BMC Pulm Med, 15, 2015, 112.
33. [33] Martin-Loeches, I., Lisboa, T., Rodriguez, A., Putensen, C., Annane, D., Garnacho-Montero, J., et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 36 (2010), 612–620.
34. [34] Menendez, R., Torres, A., Reyes, S., Zalacain, R., Capelastegui, A., Aspa, J., et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 39 (2012), 156–162.
35. [35] Minhas, R., Walker, S.A.N., Rachlis, A., Management of Community-Acquired Pneumonia at a Tertiary-Care Teaching Hospital. Can J Hosp Pharm 60 (2007), 245–256.
36. [36] Mongardon, N., Max, A., Bougle, A., Pene, F., Lemiale, V., Charpentier, J., et al. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care, 16, 2012, R155.
37. [37] Mortensen, E.M., Restrepo, M.I., Anzueto, A., Pugh, J., The impact of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care, 10, 2006, R8.
38. [38] Naucler, P., Darenberg, J., Morfeldt, E., Ortqvist, A., Henriques Normark, B., Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 68 (2013), 571–579.
39. [39] Waterer, G.W., Somes, G.W., Wunderink, R.G., Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161 (2001), 1837–1842.
40. [40] Wilson, B.Z., Anzueto, A., Restrepo, M.I., Pugh, M.J., Mortensen, E.M., Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med 40 (2012), 2310–2314.
41. [41] Sligl, W.I., Asadi, L., Eurich, D.T., Tjosvold, L., Marrie, T.J., Majumdar, S.R., Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 42 (2014), 420–432.
42. [42] Balshem, H., Helfand, M., Schunemann, H.J., Oxman, A.D., Kunz, R., Brozek, J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64 (2011), 401–406.
43. [43] Leroy, O., Saux, P., Bedos, J.P., Caulin, E., Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128 (2005), 172–183.
44. [44] Culic, O., Erakovic, V., Cepelak, I., Barisic, K., Brajsa, K., Ferencic, Z., et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 450 (2002), 277–289.
45. [45] Parnham, M.J., Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 18 (2005), 125–131.
46. [46] Dalhoff, A., Shalit, I., Immunomodulatory effects of quinolones. Lancet Infect Dis 3 (2003), 359–371.
47. [47] Waterer, G.W., Rello, J., Choosing the right combination therapy in severe community-acquired pneumonia. Crit Care, 10, 2006, 115.
48. [48] Williams, A.C., Galley, H.F., Watt, A.M., Webster, N.R., Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother 56 (2005), 502–506.
49. [49] Asadi, L., Sligl, W.I., Eurich, D.T., Colmers, I.N., Tjosvold, L., Marrie, T.J., et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 55 (2012), 371–380.
50. [50] Raz-Pasteur, A., Shasha, D., Paul, M., Fluoroquinolones or macrolides alone versus combined with beta-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. Int J Antimicrob Agents 46 (2015), 242–248.
51. [51] Drago, L., Nicola, L., Rodighiero, V., Larosa, M., Mattina, R., De Vecchi, E., Comparative evaluation of synergy of combinations of beta-lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniae. J Antimicrob Chemother 66 (2011), 845–849.
52. [52] Vardakas, K.Z., Tansarli, G.S., Bliziotis, I.A., Falagas, M.E., beta-Lactam plus aminoglycoside or fluoroquinolone combination versus beta-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents 41 (2013), 301–310.